Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 19/2023

28.10.2023 | Research

Using machine learning to identify patients at high risk of developing low bone density or osteoporosis after gastrectomy: a 10-year multicenter retrospective analysis

verfasst von: Yanfei Zhu, Yuan Liu, Qi Wang, Sen Niu, Lanyu Wang, Chao Cheng, Xujin Chen, Jinhui Liu, Songyun Zhao

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 19/2023

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Osteoporosis that emerges subsequent to gastrectomy poses a significant threat to the long-term health of patients. The primary objective of this investigation was to formulate a machine learning algorithm capable of identifying substantial preoperative, intraoperative, and postoperative risk factors. This algorithm, in turn, would enable the anticipation of osteoporosis occurrence after gastrectomy.

Methods

This research encompassed a cohort of 1125 patients diagnosed with gastric cancer, including 108 individuals with low bone density or osteoporosis. A total of 40 distinct variables were collected, comprising patient demographics, pertinent medical history, medication records, preoperative examination attributes, surgical procedure specifics, and intraoperative details. Four distinct machine learning algorithms—extreme gradient boosting (XGBoost), random forest (RF), support vector machine (SVM), and k-nearest neighbor algorithm (KNN)—were employed to establish the predictive model. Evaluation of the models involved receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Shapley additive explanation (SHAP) was employed for visualization and analysis.

Results

Among the four prediction models employed, the XGBoost algorithm demonstrated exceptional performance. The ROC analysis yielded excellent predictive accuracy, showcasing area under the curve (AUC) values of 0.957 and 0.896 for training and validation sets, respectively. The calibration curve further confirmed the robust predictive capacity of the XGBoost model. The DCA demonstrated a notably higher benefit rate for patients undergoing intervention based on the XGBoost model. Moreover, the AUC value of 0.73 for the external validation set indicated favorable extrapolation of the XGBoost prediction model. SHAP analysis outcomes unveiled numerous high-risk factors for osteoporosis development after gastrectomy, including a history of chronic obstructive pulmonary disease (COPD), inflammatory bowel disease (IBD), hypoproteinemia, postoperative neutrophil-to-lymphocyte ratio (NLR) exceeding 3, steroid usage history, advanced age, and absence of calcitonin use.

Conclusion

The osteoporosis prediction model derived through the XGBoost machine learning algorithm in this study displays remarkable predictive precision and carries significant clinical applicability.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
Zurück zum Zitat Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C et al (2012) A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the oral calcitonin in postmenopausal osteoporosis (Oracal) trial. J Bone Miner Res 27(8):1821–1829. https://doi.org/10.1002/jbmr.1602CrossRefPubMed Binkley N, Bolognese M, Sidorowicz-Bialynicka A, Vally T, Trout R, Miller C et al (2012) A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the oral calcitonin in postmenopausal osteoporosis (Oracal) trial. J Bone Miner Res 27(8):1821–1829. https://​doi.​org/​10.​1002/​jbmr.​1602CrossRefPubMed
Zurück zum Zitat Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R (2020) Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci 21(11). (Epub 20200604) https://doi.org/10.3390/ijms21114012. Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R (2020) Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. Int J Mol Sci 21(11). (Epub 20200604) https://​doi.​org/​10.​3390/​ijms21114012.
Zurück zum Zitat Pinto D, Alshahrani M, Chapurlat R, Chevalley T, Dennison E, Camargos BM et al (2022) The Global approach to rehabilitation following an osteoporotic fragility fracture: a review of the rehabilitation working group of the international osteoporosis foundation (Iof) committee of scientific advisors. Osteoporos Int 33(3):527–540. https://doi.org/10.1007/s00198-021-06240-7. (Epub 20220120)CrossRefPubMed Pinto D, Alshahrani M, Chapurlat R, Chevalley T, Dennison E, Camargos BM et al (2022) The Global approach to rehabilitation following an osteoporotic fragility fracture: a review of the rehabilitation working group of the international osteoporosis foundation (Iof) committee of scientific advisors. Osteoporos Int 33(3):527–540. https://​doi.​org/​10.​1007/​s00198-021-06240-7. (Epub 20220120)CrossRefPubMed
Zurück zum Zitat Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK et al (2018) Osteoporosis: a review of treatment options. P t 43(2):92–104PubMedPubMedCentral Tu KN, Lie JD, Wan CKV, Cameron M, Austel AG, Nguyen JK et al (2018) Osteoporosis: a review of treatment options. P t 43(2):92–104PubMedPubMedCentral
Zurück zum Zitat Yokota K, Sato K, Miyazaki T, Kitaura H, Kayama H, Miyoshi F et al (2014) Combination of tumor necrosis factor α and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo. Arthritis Rheumatol 66(1):121–129. https://doi.org/10.1002/art.38218CrossRefPubMed Yokota K, Sato K, Miyazaki T, Kitaura H, Kayama H, Miyoshi F et al (2014) Combination of tumor necrosis factor α and interleukin-6 induces mouse osteoclast-like cells with bone resorption activity both in vitro and in vivo. Arthritis Rheumatol 66(1):121–129. https://​doi.​org/​10.​1002/​art.​38218CrossRefPubMed
Metadaten
Titel
Using machine learning to identify patients at high risk of developing low bone density or osteoporosis after gastrectomy: a 10-year multicenter retrospective analysis
verfasst von
Yanfei Zhu
Yuan Liu
Qi Wang
Sen Niu
Lanyu Wang
Chao Cheng
Xujin Chen
Jinhui Liu
Songyun Zhao
Publikationsdatum
28.10.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 19/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-023-05472-w

Weitere Artikel der Ausgabe 19/2023

Journal of Cancer Research and Clinical Oncology 19/2023 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.